Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lymphocyte cholecystokinin concentrations in panic disorder

F Brambilla1, L Bellodi, G Perna

  • 1Centro di Psiconeuroendocrinologia, Ospedale Psichiatrico Pini, Milan, Italy.

The American Journal of Psychiatry
|July 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Black Hole Spectroscopy and Tests of General Relativity with GW250114.

Physical review letters·2026
Same author

GW250114: Testing Hawking's Area Law and the Kerr Nature of Black Holes.

Physical review letters·2025
Same author

Deciphering the Instability of the Black Hole Ringdown Quasinormal Spectrum.

Physical review letters·2024
Same author

Clinical outcomes and predictors of success with Impella weaning in cardiogenic shock: a single-center experience.

Frontiers in cardiovascular medicine·2023
Same author

A proof-of-concept study applying machine learning methods to putative risk factors for eating disorders: results from the multi-centre European project on healthy eating.

Psychological medicine·2021
Same author

Efficacy of bio- and neurofeedback for depression: a meta-analysis.

Psychological medicine·2021
Same journal

2026 Annual Meeting: President-Elect Address.

The American journal of psychiatry·2026
Same journal

2026 Annual Meeting: CEO and Medical Director's Address.

The American journal of psychiatry·2026
Same journal

Reports to the Membership.

The American journal of psychiatry·2026
Same journal

Convergent Metabolic Dysregulations But Divergent Contributing Pathways Across Severe Mental Disorders: The Power of Combining Genetics and Metabolomics.

The American journal of psychiatry·2026
Same journal

2026 Annual Meeting: Presidential Address.

The American journal of psychiatry·2026
Same journal

Represcribing Previously Used Antipsychotics: Response to So.

The American journal of psychiatry·2026
See all related articles

Patients with panic disorder have lower lymphocyte cholecystokinin (CCK-8) levels than healthy individuals. Alprazolam treatment did not alter these CCK-8 concentrations, suggesting CCK-8 may not be a direct biomarker for panic disorder treatment response.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Endocrinology

Background:

  • Cholecystokinin (CCK) is implicated in anxiety and panic attacks.
  • CCK-8 is a biologically active fragment of CCK.
  • Understanding CCK's role in panic disorder is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate lymphocyte cholecystokinin-8 (CCK-8) concentrations in patients with panic disorder compared to healthy controls.
  • To assess the effect of alprazolam therapy on CCK-8 levels in panic disorder patients.

Main Methods:

  • Lymphocyte CCK-8 concentrations were measured in 15 panic disorder patients and 15 healthy controls.
  • Patients received 1.5 mg/day alprazolam for 30 days, with CCK-8 levels re-measured.
  • Anxiety levels and panic attack frequency/severity were recorded.

Related Experiment Videos

Main Results:

  • Lymphocyte CCK-8 concentrations were significantly lower in panic disorder patients than in controls.
  • Alprazolam treatment did not significantly alter CCK-8 levels in patients.
  • No correlation was found between CCK-8 levels and anxiety or panic attack metrics.

Conclusions:

  • Lower lymphocyte CCK-8 levels may be associated with panic disorder.
  • Alprazolam therapy does not appear to modulate CCK-8 levels in this patient group.
  • Lymphocyte CCK-8 may not serve as a direct biomarker for treatment response in panic disorder with alprazolam.